Abiraterone
Also known as: Abiraterone Acetate
Active ingredient description
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Medicines
Abiraterone is the active ingredient of these drugs:
South Africa
Poland
Hong Kong Singapore
Ecuador
Ecuador
Brazil
Ecuador
Ecuador
Poland
Ecuador
Brazil Ecuador
Brazil
Lithuania Poland
Brazil
Ecuador
New Zealand United States
Brazil
South Africa
Australia Austria Brazil Canada Cyprus
Ecuador
Structural formula
Chemical formula: C₂₄H₃₁NO
Molecular mass: 349.509 g/mol